GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (OTCPK:DMKPQ) » Definitions » ROE %

DMK Pharmaceuticals (DMK Pharmaceuticals) ROE % : 0.00% (As of Sep. 2023)


View and export this data going back to 1995. Start your Free Trial

What is DMK Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. DMK Pharmaceuticals's annualized net income for the quarter that ended in Sep. 2023 was $-5.55 Mil. DMK Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was $-8.56 Mil. Therefore, DMK Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2023 was N/A%.

The historical rank and industry rank for DMK Pharmaceuticals's ROE % or its related term are showing as below:

DMKPQ's ROE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 4.25
* Ranked among companies with meaningful ROE % only.

DMK Pharmaceuticals ROE % Historical Data

The historical data trend for DMK Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals ROE % Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -90.46 -69.05 -270.64 -311.96 -211.19

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -355.94 -1,307.02 - - -

Competitive Comparison of DMK Pharmaceuticals's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DMK Pharmaceuticals's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where DMK Pharmaceuticals's ROE % falls into.



DMK Pharmaceuticals ROE % Calculation

DMK Pharmaceuticals's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-26.478/( (25.883+-0.808)/ 2 )
=-26.478/12.5375
=-211.19 %

DMK Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %=Net Income (Q: Sep. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Sep. 2023 ))/ count )
=-5.552/( (-11.825+-5.285)/ 2 )
=-5.552/-8.555
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


DMK Pharmaceuticals  (OTCPK:DMKPQ) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-5.552/-8.555
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-5.552 / 0.036)*(0.036 / 6.853)*(6.853 / -8.555)
=Net Margin %*Asset Turnover*Equity Multiplier
=-15422.22 %*0.0053*N/A
=ROA %*Equity Multiplier
=-81.74 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-5.552/-8.555
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-5.552 / -6.944) * (-6.944 / -13.06) * (-13.06 / 0.036) * (0.036 / 6.853) * (6.853 / -8.555)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7995 * 0.5317 * -36277.78 % * 0.0053 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


DMK Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Executives
Dorbin John W. Jr. officer: General Counsel C/O ARCIMOTO, INC., 2034 WEST 2ND AVENUE, EUGENE OR 97402
Seth Cohen officer: CFO C/O NEWTEK BUSINESS SERVICES,INC, 1440 BROADWAY, NEW YORK NY 10018
Ebrahim Versi director, officer: CEO 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Jannine Versi director 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Vickie S Reed director TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David J. Marguglio director 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Carlo Dennis J Phd director, 10 percent owner, officer: President/CEO PO BOX 1176, RANCHO SANTA FE CA 92067
Ronald B. Moss officer: Chief Medical Officer 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
David C. Benedicto officer: Chief Financial Officer 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Meera J. Desai director 1682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Robert O Hopkins officer: Chief Financial Officer 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Karen K. Daniels officer: Vice President of Operations 11455 EL CAMINO REAL, SUITE 310, SAN DIEGO CA 92130
Howard C Birndorf director C/O NANOGEN INC, 10398 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Roshawn A. Blunt director 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Richard C Williams director 26001 OSPREY NEST COURT, BONITA SPRINGS FL 34134